“Tocilizumab Reduces Procalcitonin Levels in COVID-19 Patients, Challenging Its Use as Bacterial Superinfection Predictor”

https://pubmed.ncbi.nlm.nih.gov/38112371

The study found that tocilizumab administration in COVID-19 patients significantly reduces procalcitonin levels, suggesting that it may not be a reliable predictor of superinfection with bacteria.